Elicio Therapeutics announced it will present new data from its Phase 2 AMPLIFY-7P trial of camupepimut, a KRAS-targeted immunotherapy for pancreatic cancer, at the SITC 2026 Annual Meeting. The trial evaluates camupepimut versus observation in patients with KRAS-mutated pancreatic cancer after standard therapy. Results highlight immune responses linked to better clinical outcomes, supporting camupepimut's potential as an off-the-shelf treatment. Further details will be shared in keynote and poster sessions at the conference in November 2026.
Elicio Therapeutics' Phase 2 AMPLIFY-7P trial results presentation is the subject, with Pluang data showing that out of 150 priced Health-sector US stocks, 91 rose and 53 fell today. Notable movers include Amgen (AMGN) at USD 468.69 with a 3.73% gain and 82% buy order activity, Baxter International (BAX) at USD 26.40 up 3.69%, and Vertex Pharmaceuticals (VRTX) at USD 548.49 rising 3.55% with a typical hold time of 122 days. This snapshot is as of Oct 29, 2026 19:12 WIB.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
